key: cord-0761877-zptmoqur
authors: Sinha, Pratik; Furfaro, David; Cummings, Matthew J.; Abrams, Darryl; Delucchi, Kevin; Maddali, Manoj V.; He, June; Thompson, Alison; Murn, Michael; Fountain, John; Rosen, Amanda; Robbins-Juarez, Shelief Y.; Adan, Matthew A.; Satish, Tejus; Madhavan, Mahesh; Gupta, Aakriti; Lyashchenko, Alexander K.; Agerstrand, Cara; Yip, Natalie H.; Burkart, Kristin M.; Beitler, Jeremy R.; Baldwin, Matthew R.; Calfee, Carolyn S.; Brodie, Daniel; O’Donnell, Max R.
title: Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids
date: 2021-03-30
journal: Am. j. respir. crit. care med
DOI: 10.1164/rccm.202105-1302oc
sha: 05ed8b513389e2f1086a1d18efa9ea8b2a9ff6a0
doc_id: 761877
cord_uid: zptmoqur

RATIONALE: Two distinct subphenotypes have been identified in acute respiratory distress syndrome (ARDS), but the presence of subgroups in ARDS associated with coronavirus disease (COVID-19) is unknown. OBJECTIVES: To identify clinically relevant, novel subgroups in COVID-19–related ARDS and compare them with previously described ARDS subphenotypes. METHODS: Eligible participants were adults with COVID-19 and ARDS at Columbia University Irving Medical Center. Latent class analysis was used to identify subgroups with baseline clinical, respiratory, and laboratory data serving as partitioning variables. A previously developed machine learning model was used to classify patients as the hypoinflammatory and hyperinflammatory subphenotypes. Baseline characteristics and clinical outcomes were compared between subgroups. Heterogeneity of treatment effect for corticosteroid use in subgroups was tested. MEASUREMENTS AND MAIN RESULTS: From March 2, 2020, to April 30, 2020, 483 patients with COVID-19–related ARDS met study criteria. A two-class latent class analysis model best fit the population (P = 0.0075). Class 2 (23%) had higher proinflammatory markers, troponin, creatinine, and lactate, lower bicarbonate, and lower blood pressure than class 1 (77%). Ninety-day mortality was higher in class 2 versus class 1 (75% vs. 48%; P < 0.0001). Considerable overlap was observed between these subgroups and ARDS subphenotypes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR cycle threshold was associated with mortality in the hypoinflammatory but not the hyperinflammatory phenotype. Heterogeneity of treatment effect to corticosteroids was observed (P = 0.0295), with improved mortality in the hyperinflammatory phenotype and worse mortality in the hypoinflammatory phenotype, with the caveat that corticosteroid treatment was not randomized. CONCLUSIONS: We identified two COVID-19–related ARDS subgroups with differential outcomes, similar to previously described ARDS subphenotypes. SARS-CoV-2 PCR cycle threshold had differential value for predicting mortality in the subphenotypes. The subphenotypes had differential treatment responses to corticosteroids.

A substantial proportion of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop the acute respiratory distress syndrome (ARDS) (1) (2) (3) (4) . Despite emerging treatment options for coronavirus disease , such as dexamethasone and IL-6 receptor antagonists, mortality among patients with COVID-19-related ARDS remains high (5, 6) . Although some prognostic features in severe COVID- 19 have been identified, the determinants of the individual variability in treatment response and outcomes remain incompletely understood (1) (2) (3) .

ARDS not associated with COVID-19 is characterized by clinical and biological heterogeneity, which has been implicated as a contributing factor in negative clinical trials aimed at developing treatment strategies (7, 8) . To address this heterogeneity, prior work has consistently identified two subphenotypes in non-COVID-19-related ARDS defined by differential profiles of inflammation, organ failure, and outcomes, as well as responses to randomized treatment interventions (9) (10) (11) . Recently, these two subphenotypes (hyperand hypoinflammatory) were identified in a small cohort of 39 patients with COVID-19-related ARDS (12) . However, it remains unclear whether distinct biological and clinical subgroups exist in COVID-19-related ARDS and whether these subgroups are distinct from previously described non-COVID-19related ARDS subphenotypes.

The primary objective of this study was to identify novel subgroups in COVID-19-related ARDS using minimally biased clustering methods and to evaluate the clinical and prognostic relevance of any resulting subgroups using 90-day outcome data. Using a previously described clinical classifier model, we also set out to compare any identified COVID-19-related ARDS subgroups with the previously described hypo-and hyperinflammatory ARDS subphenotypes (13) .

Among adult (age > 18) patients admitted to the ICUs at two hospitals affiliated with NewYork-Presbyterian Hospital/Columbia University Irving Medical Center (NYP/ CUIMC) from March 2, 2020, through April 30, 2020, patients were included in this study if they fulfilled the following criteria: 1) had a positive PCR test for SARS-CoV-2, 2) required invasive mechanical ventilation (IMV), and 3) met criteria for ARDS, using the Berlin definition based on a review of clinical data and chest radiographs assessed by critical care physicians (4) . Exclusion criteria included death before ICU admission, tracheostomy before ICU admission, or endotracheal intubation before transfer from an outside hospital. The latter group was excluded owing to lack of consistent available clinical data within 24 hours of intubation for patients transferred already on IMV and to mitigate potential selection bias of which patients were transferred during the early surge of the pandemic in New York City. Unless stated otherwise, all laboratory, ventilatory, and vital sign variables used for analysis were recorded on the initial day of IMV. The study was approved by the institutional review board at CUIMC.

Electronic medical records were reviewed for data on demographic, clinical, and laboratory variables for all included patients. Vital signs, ventilatory measurements, and routine laboratory studies that resulted within 24 hours of initiation of IMV were used for analysis. For blood-based biomarkers (IL-6, B-type natriuretic peptide, high-sensitivity C-reactive protein, D-dimer, ferritin, lactate dehydrogenase, lactate, high-sensitivity cardiac troponin T, procalcitonin, international normalized ratio, and activated partial thromboplastin time), data were extracted when measured as part of clinical care. For patients without IL-6 measured clinically, prospectively stored samples were tested, methods of which are described below. Using latent class analysis, we identified two subgroups among a cohort of 483 patients with COVID-19-related ARDS. Class 2 patients had higher inflammatory markers and lactate and corresponded with the previously identified hyperinflammatory subphenotype, whereas class 1 corresponded with the hypoinflammatory subphenotype. Class 2 had significantly higher 90-day mortality than class 1 (75% vs. 48%; P , 0.0001). Differential response to corticosteroid treatment was observed, with decreased mortality in steroidtreated patients in class 2 but not class 1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR cycle threshold was a predictor of mortality in class 1, but not class 2, suggesting distinct drivers of mortality among classes.

Interventions delivered throughout hospitalization were recorded, including targeted treatments for COVID-19 (e.g., corticosteroids, IL-6 receptor antagonists), receipt of tracheostomy, vasopressor use, renal replacement therapy, and advanced therapies for ARDS (neuromuscular blockade, ventilation in the prone position, and extracorporeal membrane oxygenation).

The primary outcome of this study was vital status at 90 days after intubation. Secondary outcomes included vital status at 28 and 180 days after intubation, ICU length of stay, and ventilator-free days at 90 days after intubation. For the primary outcome, follow-up time was right censored on July 29, 2020, so that each patient had at least 90 days of observation.

Clinical data including demographics, vital signs, and laboratory values were evaluated as class-defining variables for latent class analysis (LCA). Demographics and vital signs were used in accordance with LCA for prior ARDS subphenotyping (9) (10) (11) . The study design enabled inclusion of several novel laboratory and respiratory variables that were not used in prior LCA studies, such as lactate, troponin, procalcitonin, ferritin, and ventilatory ratio (14) . Variables with .25% missingness (Table E1 in the online  supplement) , those with .15% of values outside the upper limit of assay detection, and highly correlated variables were excluded from the LCA (see the online supplement for details). Clinical outcomes and illness severity scores were not included as classdefining variables, and modeling was performed agnostic of these variables. The variables used for LCA are summarized in Table E2 .

For LCA, we fit four sequential models consisting of 1-4 classes. The LCA algorithms used were similar to those in our prior studies and are described further in the online supplement (9) (10) (11) . The best-fitting model was selected based on the Bayesian information criteria, entropy, and the Vuong-Lo-Mendall-Ruben test (15) . Once the best model was selected, an individual patient's class assignment was determined by the highest probability of class membership (>0.5). LCA was performed using Mplus8 editor version 1.7.

To compare the overlap of the newly identified COVID-19-related ARDS subgroups with previously described ARDS subphenotypes, we estimated the probabilities of belonging to the hyperinflammatory subphenotype using a previously validated clinical classifier model (16) . Given that COVID-19-related ARDS has a uniform etiology and the demographics of the study population were markedly different from those in which the clinical classifier models were developed, we applied a model composed of vital signs and laboratory values only. In the original study, this model had an area under the receiver operator characteristics curve of 0.94 for discriminating ARDS subphenotypes (16) . The variables used in the clinical classifier model are described in Table E2 . A probability of >0.5 was used to assign patients to the hyperinflammatory subphenotype, and ,0.5 to the hypoinflammatory subphenotype.

Given the uncertain validity of standard critical care scoring systems such as Acute Physiology and Chronic Health Evaluation-II and Sequential Organ Failure Assessment (SOFA) scores in COVID-19, to evaluate the additional prognostic value of the identified LCA classes in comparison with cohortspecific mortality predictors in COVID-19-related ARDS, we used a supervised learning approach to identify the most important variables in predicting mortality in our cohort (12, 17) . The rationale for developing these models was to identify the most important variables, among those used in the LCA modeling, in predicting mortality in this cohort. The models were not intended as a clinical prediction tool. Specifically, we used XGBoost, a gradient boosted tree algorithm, to train a model to predict mortality at Day 90 from intubation (primary outcome). Predictor variables used in this model are described in Table E2 . Variable importance was calculated using the split gain for each variable across the different trees in the model. The analyses were performed using the R package XGBoost and algorithmic procedures are detailed in the online supplement.

Biospecimens were obtained from the Columbia University Biobank, which is supported by the Irving Institute for Clinical and Translational Research and Columbia University's Clinical and Translational Science Award. For patients who did not have IL-6 measured clinically, IL-6 was quantified in prospectively banked serum samples using the Human IL-6 Quantikine ELISA Kit (R&D Systems), the same assay that was used on clinical samples. SARS-CoV-2 PCR testing was performed on nasopharyngeal swab samples. PCR was performed in the clinical microbiology laboratory at CUIMC using platforms that amplify the Envelope (E) gene within the SARS-CoV-2 genome (cobas 6800 [Roche Molecular Systems] and Infinity [Cephid Inc]). Cycle threshold (CT)-the number of PCR cycles required to reach the fluorescent threshold for a positive test-was recorded if PCR tests were positive within 7 days of intubation (18) (19) (20) (21) . Most CT values (60%) were within 24 hours of intubation and 80% were within 3 days.

Comparison between groups was performed using t tests, Wilcoxon-rank sum, or Pearson's chi-square tests, depending on the distribution of the variable. Kaplan-Meier survival curves, censored at Day 90, were plotted to compare survival across groups. For evaluation of the prognostic value of individual variables and for exploration of treatment interaction between subphenotypes and corticosteroid exposure, logistic regression models were used to estimate odds ratios, with mortality at Day 90 as the dependent variable. Analyses were performed in RStudio (version 1.1.453) using R (version 4.0.1) or in STATA/IC version 16.1 (StataCorp LLC).

Of 558 screened patients, 483 were included in this analysis ( Figure E1 and Table 1 , and median ventilator-free days was 0 (IQR, 0-57).

Fit statistics for the LCA models are presented in Table 2 . As model complexity increased, Bayesian information criteria decreased, with the greatest decrease observed between a 1-class and 2-class model. The 2-class model was a significantly better fit than the 1-class model (Vuong-Lo-Mendall-Ruben P = 0.0075), whereas the 3-class and 4-class models were not significant improvements over a model comprising one fewer class. Together, the data were indicative of the 2-class model best fitting the population.

In the 2-class model, 373/483 (77%) of the patients were assigned to class 1 and 110/ 483 (23%) to class 2. Indicative of robust class allocation, the mean probabilities for class assignment were 0.96 (60.09) and 0.92 (60.12) for COVID-19-related ARDS class 1 and COVID-19-related ARDS class 2, respectively. Demographic differences between classes are summarized in Table 1 . Patients assigned to COVID-19-related ARDS class 2 were significantly older (67 vs. 63 years, P = 0.0026), and a higher proportion were Hispanic (62% vs. 49%, P = 0.016). The proportions of patients with hypertension and diabetes mellitus were similar across the two classes ( Figure E2 ).

COVID-19-related ARDS class 2 was associated with higher levels of lactate, troponin, procalcitonin, and creatinine ( Figure 1 ). Proinflammatory markers such as IL-6 and ferritin were also significantly higher in COVID-19-related ARDS class 2, whereas levels of albumin and bicarbonate were significantly lower. Among the relevant biomarkers not included in the LCA, D-dimer and C-reactive protein were higher in COVID-19-related ARDS class 2. However, the latter failed to reach statistical significance ( Figure E3 ). Except for ventilatory ratio, which was higher in class 2, no significant differences were observed between the COVID-19-related ARDS classes in respiratory variables ( Figure E4 ). Compared with COVID-19-related ARDS Definition of abbreviation: BIC = Bayesian information criteria. Each row represents a single model comprising K classes. N1-N4 are the number of observations in each class and the P value represents the Vuong-Lo-Mendell-Rubin test, which tests whether a model comprising a K class is a better fit than a K-1 class. *Seventeen perturbed starting value run(s) did not converge or were rejected in the third stage. class 1, COVID-19-related ARDS class 2 patients had significantly higher mortality at 90 days and had fewer ventilator-free days ( Table 3) .

Using the clinical classifier model, 341/483 (71%) patients were classified as the hypoinflammatory ARDS subphenotype and 142/483 (29%) were classified as the hyperinflammatory ARDS subphenotype. Eighty-six percent of the COVID-19-related ARDS class 1 patients were classified to the hypoinflammatory subphenotype, and 81% of the COVID-19-related ARDS class 2 patients were classified into the hyperinflammatory subphenotype ( Figure 2 ). Among patients who crossed over to the noncorresponding subgroup (e.g., class 1 to the hyperinflammatory subphenotype), their probability of subgroup assignment was significantly lower compared with those patients who classified into their corresponding subgroups ( Figure E5 ), suggesting greater uncertainty in subgroup membership in these patients. As expected, differences between the two ARDS subphenotypes in demographics, ventilatory variables, and biomarkers were similar in their patterns to those observed between the two COVID-19-related ARDS classes (Table 4 ) and to the non-COVID-19-related ARDS subphenotypes described in the literature (13, 22) . Of note, unlike the COVID-19-related ARDS classes, age across the two ARDS subphenotypes was similar.

Clinical outcomes trends observed among patients in the hyperinflammatory and hypoinflammatory subphenotypes were similar to their corresponding COVID-19-related ARDS classes (Table 3 ). In COVID-19-related ARDS class 1 ( Figure  3A ) and the hypoinflammatory subphenotype ( Figure 3B ), there was a survival advantage observed early in the observation period that persisted to 90 days.

The XGBoost bootstrapped model trained to predict mortality at Day 90 had an area under the receiver operator characteristics curve of 0.84 (95% confidence interval [CI], 0.81-0.88). The top 10 most important variables in the model are presented in Figure 4 and are consistent with those described in several other studies (23) (24) (25) . The several-fold higher importance values of age and troponin in comparison with other predictors in the model indicate that these two variables were the key predictors of mortality in this cohort. Among the top 10 predictor variables, age, compliance, glucose, international normalized ratio, body mass index, and CT did not feature prominently as partitioning variables in the LCA model, suggesting that the prognostic value of the LCA classes is independent of common predictors of mortality in COVID-19-related ARDS.

CT was an unexpected finding among the top 10 important predictor variables for mortality in COVID-19-related ARDS. When evaluated further, we found that higher CT was associated with decreased risk of mortality (odds ratio, 0.95 per unit increase in CT; 95% CI, 0.91-0.98) and remained so after adjusting for age, sex, body mass index category, race, and SOFA score (odds ratio, 0.95; 95% CI, 0.91-0.99). There was no significant difference in CT values between the hyper-and hypoinflammatory subphenotypes (P = 0.9482). When stratified by subphenotypes, CT values were similar among survivors and nonsurvivors in the hyperinflammatory subphenotype; however, CT values were significantly lower in nonsurvivors in the hypoinflammatory subphenotype ( Figure 5 ). When the subphenotypes were dichotomized into subgroups by the population median of CT (.27.07 "CT high," ,27.07 "CT low"), no significant difference in mortality was observed in the hyperinflammatory subphenotype (CT high 66% vs. 69% CT low; P = 0.8970). In contrast, in the hypoinflammatory subphenotype, mortality was significantly lower in the CT-high subgroup than in the CT-low group (42% vs. 56%; P = 0.0149). These findings were the same when evaluated in the COVID-19-related ARDS classes (data not presented).

In a logistic regression model, the interaction term between ARDS subphenotype and corticosteroid exposure for 90-day mortality was significant (P = 0.0295). Corticosteroid exposure was associated with a trend toward decreased mortality in the hyperinflammatory phenotype and increased mortality in the hypoinflammatory phenotype ( Table 5 ). The model was adjusted for SOFA score to account for indication bias, and the interaction term remained statistically significant (P = 0.0410). The interaction term for corticosteroid therapy and COVID-19-related ARDS classes was also significant, for both the unadjusted (P = 0.0273) and the adjusted model (P = 0.0370).

In this study, we used a minimally biased approach to discover two novel subclasses in COVID-19-related ARDS. These classes have distinct biological and clinical characteristics with divergent clinical outcomes. Class 2 was associated with increased markers of inflammation, lower bicarbonate, and a higher prevalence of multiorgan failure. Using a previously validated machine learning model, we were able to classify patients with COVID-19-related ARDS into previously described hypo-and hyperinflammatory ARDS subphenotypes (9-12, 16, 26) . There was consistent overlap in the characteristics and clinical outcomes between the two phenotyping schemes, in which COVID-19-related ARDS class 2 corresponded to the hyperinflammatory subphenotype. Mortality among the entire cohort and within each subphenotype and COVID-19-related ARDS class was substantially higher than that observed in historical non-COVID-19-related ARDS studies (1-3, 6, 7). Furthermore, we observed an association of lower PCR-CT, a surrogate for viral load, with increased mortality in the cohort overall; however, this finding was largely driven by the hypoinflammatory subphenotype (19) . We observed a significant interaction between the subgroups identified and corticosteroid exposure, in which treatment was associated with improved survival in the hyperinflammatory subphenotype but not the hypoinflammatory subphenotype.

In the absence of a validation cohort, the overlap of COVID-19-related ARDS classes 1 and 2 with the hypo-and hyperinflammatory subphenotypes, respectively, is a reassuring finding and lends validity to the observed differences between these subgroups. It is likely that class 2 characterizes a more severe or "specific" subset of the hyperinflammatory subphenotype given the smaller number of patients, higher prevalence of multiorgan failure, and increased mortality. In prior ARDS phenotyping studies, markers such as procalcitonin, lactate, and ferritin were not available (9) (10) (11) . However, given the biological characteristics of the hyperinflammatory subphenotype, it is unsurprising that these new markers were also elevated. As these biomarkers are more widely available in clinical laboratories than research biomarkers such as IL-6, IL-8, and soluble tumor necrosis factor-1, their use may facilitate more widespread identification of ARDS subphenotypes and warrants further evaluation.

In comparison with a prior study (n = 39) describing the prevalence of the ARDS subphenotypes in COVID-19-related ARDS, the proportion of patients in the hyperinflammatory phenotype was higher in our study (12) . The sample size and method for defining the phenotypes differed between the studies; nevertheless, the true prevalence of these subphenotypes in COVID-19-related ARDS and their key determinants remains unknown and needs mapping in future studies. Among these determinants, the relative influence of race and ethnicity, genetic polymorphisms, viral variants, and the use of early immunomodulators also warrant investigation.

Within this observational cohort, the main clinical value of the subphenotypes was to identify an at-risk COVID-19-related ARDS group with distinct biological characteristics. Consistent with several other studies, age was the most important variable in our supervised XGBoost mortality-predicting model (1) (2) (3) 16 ). Yet age was not significantly different between the two ARDS subphenotypes. Several of the top 10 variables in the supervised model were not important partitioning variables in either the COVID-19-related ARDS classes or the ARDS subphenotypes, suggesting that the prognostic information from the subphenotypes cannot be easily captured using standard prognostication approaches. A second advantage of the presented phenotyping schema is that it stratifies the COVID-19-related ARDS population into less heterogeneous subgroups. Although the etiological insult in COVID-19 may be uniform, our data support the hypothesis that at the onset of ARDS, considerable biological heterogeneity exists within this population. It stands to reason that immunomodulatory interventions such as corticosteroids and IL-6 inhibitors may have differential efficacy across such biological subphenotypes, a heterogeneity in treatment effect. The trend toward improved mortality with corticosteroid therapy in the hyperinflammatory subphenotype and worse outcomes in the hypoinflammatory subphenotype substantiate this hypothesis.

How do we reconcile the findings of heterogeneity of treatment effect with corticosteroids in the ARDS subphenotypes with the evidence in the literature of improved outcomes in COVID-19? First, it is important to acknowledge that ours was a retrospective observational cohort and limited to nonrandomized allocation of treatment. Although we note that corticosteroid treatment was equally as common in the hyper-and hypoinflammatory subphenotypes (67% in each), the dose and type of steroids used differed across the population. The proportion of patients receiving each type of corticosteroid, however, was insufficiently large to perform subgroup analyses. Given the constraints of the study design, interpretation of the presented findings should be cautious and limited to hypothesis generation.

Within this context, in the RECOVERY (Randomised Evaluation of COVID-19 Therapy)-Dexamethasone trial, there was evidence of heterogeneity in treatment effect depending on the severity of illness, with a signal to harm in those not requiring oxygen support and the largest benefit in those who were invasively ventilated (6) . In three of the largest clinical trials that tested the benefit of corticosteroids specifically in critically ill patients, no significant reduction in absolute mortality was observed: CODex (COVID-19 Dexamethasone) (P = 0.85), CAPE COVID (Community-Acquired Pneumonia: Evaluation of Corticosteroids in Coronavirus Disease) (P = 0.057), and REMAP-CAP (A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia) (P values not available but the confidence intervals for the odds ratio of mortality crossed unity for both treatment groups) (27) (28) (29) . Notably, in all these trials, there was a signal to morality benefit with corticosteroid therapy, suggesting that treating specific subphenotypes may have resulted in significantly improved mortality, and that further evaluation is warranted (30) . Furthermore, in our cohort, the ratio of signal to harm in the hypoinflammatory subphenotype was small. Given the large proportion of patients in this subphenotype, it is highly likely that subsumed within it is a smaller subset of patients who may be harmed with corticosteroid use. Given the known linkage between corticosteroids and delayed viral clearance, patients with high viral load may be an interesting group to investigate in future studies.

To that end, heterogeneity of treatment effect may also help explain the modest absolute reduction in mortality in immunomodulators such as IL-6 inhibitors (5, 6, 31-33). Of note, in the recent RECOVERY trial evaluation of tocilizumab in COVID-19, mortality among mechanically ventilated patients approached 50% regardless of the treatment arm, which is similar to our cohort (5) . Although overall ICU mortality in COVID-19 has declined over the course of the pandemic, among invasive mechanically ventilated patients, case fatality rates in a large meta-analysis were also similar to those described in our cohort, albeit with considerable regional variation (34) . The mortality rate in our cohort was higher than that in some studies from a similar time period; however, we note that, unlike our study, these studies included all intubated patients, not just those who met ARDS criteria, and did not report 90-day mortality (35) (36) (37) . Several key determinants of the variance in outcomes in COVID-19 have been described; among these, acute physiology, socioeconomic factors, and hospital strain were most pertinent to our cohort and may explain its high mortality (38) . ICU strain and demand due to the surge of COVID-19 cases in New York City during the study period may have been of particular importance given their association with worse outcomes (39, 40) .

This study also highlights the advantage of evaluating prognostic markers within subphenotypes. Consistent with other reports, SARS-CoV-2 PCR-CT, a surrogate for viral load, was associated with mortality in the entire cohort after adjusting for age and illness severity (18) (19) (20) (21) . Interestingly, this association with mortality was primarily observed in the hypoinflammatory subphenotype. In view of these findings, we hypothesize that viral cytotoxicity may be a primary driver of mortality in the hypoinflammatory subphenotype, whereas in the hyperinflammatory subphenotype, mortality may be driven by excessive inflammation, as evidenced by higher levels of proinflammatory markers and increased prevalence of multiorgan failure. It is also interesting to note a trend toward increased mortality with corticosteroids in the hypoinflammatory phenotype, given that their use has been implicated in delayed viral clearance in SARS-CoV-1, Middle East respiratory syndrome coronavirus, and influenza pneumonia (41) (42) (43) . The subphenotype-specific association of PCR-CT with mortality reinforces the argument against a "one-size fits-all approach" to pharmacotherapies in COVID-19-related ARDS. Although PCR-CT has been related to viral load in clinical samples, the precise relationship between the quantified levels of PCR-CT and viral load is inconsistently defined across assays (44) . Therefore, the findings of our study need external validation.

In prior studies, ventilatory and gas exchange variables such as Pa O 2 /FI O 2 and compliance have consistently been similar between the two ARDS subphenotypes. In a novel analysis in this study comparing ventilatory ratio (VR), a bedside surrogate for dead space, we observed higher values in the hyperinflammatory subphenotype than in the hypoinflammatory subphenotype (14) . In contrast, the subphenotypes had similar Pa O 2 / FI O 2 ratios, driving pressures, and compliance, indicating that the difference in VR is likely not explained by ARDS severity alone. High dead space fractions have been reported in COVID-19-related ARDS, but the difference compared with ARDS from other etiologies and its prognostic value in COVID-19 are still areas of investigation (45, 46) . The pathophysiologic and biologic mechanism underlying the difference in VR between the subphenotypes warrants further investigation. One possible hypothesis could be the higher incidence of thromboembolism in the lung microvasculature that has been reported in COVID-19-related ARDS (47) . However, advanced imaging to confirm the increased prevalence of _ V/ _ Q mismatch of the lungs was not available in our cohort, and this hypothesis requires substantial further investigation.

Our study has several strengths. First, missingness among predictor variables was low. The primary outcome was 90-day mortality and therefore captured vital status over an extended time period. We were able to identify subphenotypes based on a composite of clinical and biological features using minimally biased methods that were agnostic to outcomes, and most of the biomarkers used are widely available in clinical laboratories. To our knowledge, this is one of the largest studies of COVID-19-related ARDS that has evaluated PCR-CT as a predictor of outcome.

The study also has several limitations. Our study captures data from early in the pandemic and from a single center; management strategies have since changed and overall mortality declined in this rapidly evolving pandemic. There was high demand for ICU beds during the study period and considerable hospital and ICU strain, which may limit the external validity of the study. Another limitation is the lack of a second independent cohort in which to replicate the COVID-ARDS LCA findings; however, the substantial overlap with previously validated ARDS subphenotypes reinforces the likely generalizability of these findings. PCR-CT was measured at a single time point, and thus, we were unable to test its prognostic value over time. Patients in the cohort all presented in the early part of the pandemic in which treatment approaches were less uniform than current practices, which are informed by the results of emerging clinical trials. Use of some therapies, for example, immunomodulatory drugs, may have had an influence on the circulating levels of class-defining variables and thereby had a confounding influence on the identified classes. The use of such therapies was insufficiently prevalent in our population to adequately define this phenomenon. Finally, because of resource constraints at our study site throughout the initial phase of the pandemic, prone positioning was used relatively infrequently during the study period. This practice may have influenced our outcome data, as prone positioning is known to improve mortality among patients with moderate to severe ARDS. It is notable, however, that the mortality rate observed was similar to that seen in other studies of COVID-19-related ARDS (2, 5, 6) .

In summary, we identified two distinct subclasses of COVID-19-related ARDS that were remarkably similar in clinical characteristics and outcomes to previously established ARDS subphenotypes. COVID-19-related ARDS class 2 and the hyperinflammatory subphenotype were associated with adverse clinical outcomes. We observed that PCR-CT was associated with increased mortality in the hypoinflammatory subphenotype but not the hyperinflammatory phenotype. Finally, heterogeneous treatment responses were observed with corticosteroid use in the subphenotypes. Further studies should focus on replicating distinct subphenotypes within COVID-19-related ARDS as well as on identifying factors that influence differential response to treatment within severe COVID-19.

Author disclosures are available with the text of this article at www.atsjournals.org.

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, openlabel, platform trial

RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19

LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries

Phenotypes in acute respiratory distress syndrome: moving towards precision medicine

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials

Irish Critical Care Trials Group. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial

Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study

Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials

Physiologic analysis and clinical performance of the ventilatory ratio in acute respiratory distress syndrome

Practitioner's guide to latent class analysis: methodological considerations and common pitfalls

Machine learning classifier models can identify acute respiratory distress syndrome phenotypes using readily available clinical data

Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation

Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019

A systematic review of the clinical utility of cycle threshold values in the context of COVID-19

SARS-CoV-2 viral load predicts COVID-19 mortality

WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research

Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study

Machine learning based clinical decision support system for early COVID-19 mortality prediction

Development and validation of prognosis model of mortality risk in patients with COVID-19

Comparing machine learning algorithms for predicting ICU admission and mortality in COVID-19

Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy

COALITION COVID-19 Brazil III Investigators. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial

CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial

Writing Committee for the REMAP-CAP Investigators. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial

Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Interleukin-6 receptor antagonists in critically ill patients with Covid-19

Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. a meta-analysis

and the Emory COVID-19 Quality and Clinical Research Collaborative. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019

Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study

Respiratory mechanics and gas exchange in COVID-19-associated respiratory failure

STOP-COVID Investigators. Hospital-level variation in death for critically ill patients with COVID-19

Association of intensive care unit patient load and demand with mortality rates in US Department of Veterans Affairs hospitals during the COVID-19 pandemic

Association between caseload surge and COVID-19 survival in 558 U.S. hospitals

Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome

Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients

Viral loads and duration of viral shedding in adult patients hospitalized with influenza

Important issues to consider before interpreting and applying Ct values in clinical practice

Ventilatory ratio in hypercapnic mechanically ventilated patients with COVID-19-associated acute respiratory distress syndrome

PRoVENT-COVID Study Group. Dead space estimates may not be independently associated with 28-day mortality in COVID-19 ARDS

Pathophysiology of the acute respiratory distress syndrome: insights from clinical studies

The authors thank the patients treated at Columbia University Irving Medical Center and their families. They also thank the healthcare workers who risked their own well-being to provide outstanding care during the COVID-19 pandemic.